Patents Examined by M Franco G Salvoza
  • Patent number: 11939355
    Abstract: The present disclosure provides AAV variants that exhibit a preference for retrograde movement in neurons and methods of using such variants.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: March 26, 2024
    Assignee: Howard Hughes Medical Institute
    Inventors: Joshua Dudman, Adam Hantman, Bum-Yeol Hwang, Alla Karpova, Loren Looger, Kimberly Ritola, David Schaffer, Dougal Gowanlock Robinson Tervo, Sarada Viswanathan
  • Patent number: 11931480
    Abstract: A hydrogel material for modulating an immune response in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces formed between the microgel particles and wherein the collection of microgel particles further includes at least one of an antigen and an adjuvant.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: March 19, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Philip Scumpia, Donald R. Griffin
  • Patent number: 11931481
    Abstract: A hydrogel material for use in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having pores formed between the microgel particles wherein the pores are substantially devoid of hydrogel.
    Type: Grant
    Filed: July 30, 2022
    Date of Patent: March 19, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dino Di Carlo, Westbrook Weaver, Tatiana Segura, Jaekyung Koh, Philip Scumpia, Donald R. Griffin
  • Patent number: 11926839
    Abstract: The present invention includes compositions and methods for T cell genome editing and screening in vivo. In certain aspects, the invention includes an sgRNA library for genome-scale mutagenesis.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: March 12, 2024
    Assignee: YALE UNIVERSITY
    Inventors: Sidi Chen, Matthew Dong
  • Patent number: 11926841
    Abstract: The present invention relates to a cell comprising (aa) a nucleic acid comprising in 5? to 3? direction (i) at least one adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence; (ii) a promoter which is capable of being activated by (a) helper polypeptide(s) and optionally (a) helper polynucleotide(s); and (iii) a transgenic coding sequence under the control of said promoter of (aa)(ii); and (ab) a nucleic acid comprising in 5? to 3? direction (i) a promoter which is capable of being activated by said helper polypeptide(s) and optionally said helper polynucleotide(s); and (ii) at least one AAV rep gene coding sequence under the control of said promoter of (ab)(i); wherein said cell does not comprise an AAV cap gene and/or is not able to express any AAV cap gene product.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: March 12, 2024
    Inventors: Ulrich Koszinowski, Simona Langer, Zsolt Ruzsics, Christian Thirion
  • Patent number: 11919925
    Abstract: Provided herein are methods of performing viral filtration on a fluid including a recombinant antibody, and the use of these methods in methods of manufacturing or producing the recombinant antibody.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: March 5, 2024
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bianca Olson, Saravanamoorthy Rajendran, Ryan Tedstone
  • Patent number: 11911457
    Abstract: The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: February 27, 2024
    Assignee: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Krishna Murthy Ella, Vijaya Kumar Daram
  • Patent number: 11913953
    Abstract: The present invention relates to compositions and methods involving diagnostic tests with multiple test antigens. The present invention involves the expanded use of test antigens as cross-reactive control antigens (CCAs). The invention advantageously provides for enhanced test results analysis by simultaneously providing both test antigen and CCA signal results. These results, in turn, allow useful sample comparison and cross-reference between samples to more accurately identify and verify the fidelity of test results obtained for multiple infective agents at once. The present invention may include compositions and methods for detecting infection by Zika virus or another flavivirus, and may distinguish between infections caused by genetically similar agents.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: February 27, 2024
    Assignee: InBios International, Inc.
    Inventors: James William Needham, Syamal Raychaudhuri
  • Patent number: 11905524
    Abstract: Provided herein are compositions and methods for packaging a recombinant adeno-associated vims (rAAV) particle comprising using inverted terminal repeats (ITRs) and rep genes of different serotypes and/or using chimeric rep genes.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: February 20, 2024
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Mavis Agbandje-McKenna, Mario Mietzsch, Robert McKenna
  • Patent number: 11896635
    Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 13, 2024
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Ken-ichiro Kosai, Nobuhiro Ijichi
  • Patent number: 11896664
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: February 13, 2024
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Patent number: 11896660
    Abstract: Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: February 13, 2024
    Assignee: Seqirus UK Limited
    Inventor: Nicola Groth
  • Patent number: 11897940
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 13, 2024
    Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11883488
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: January 30, 2024
    Assignee: Abacus Bioscience, Inc.
    Inventors: Edward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Patent number: 11872281
    Abstract: Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 16, 2024
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Taco Gilles Uil, Soumitra Roy, Selina Khan, Jerôme H. H. V. Custers
  • Patent number: 11865150
    Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of UFM1 activity or expression and/or an inhibitor of UFL1 activity or expression to reduce a cancer cell's ability to carry out a DDR, thereby increasing the sensitivity of cancer cells to treatment with a DNA damaging therapy such as radiation or chemotherapy, are provided.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: January 9, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Evanthia Galanis, S. Keith Anderson, Cheyne B. Kurokawa, Ianko D. Iankov
  • Patent number: 11865185
    Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 9, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), NANTES UNIVERSITE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Mathieu Mevel, David Deniaud, Eduard Ayuso
  • Patent number: 11859199
    Abstract: An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 2, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Stefano Colloca
  • Patent number: 11845778
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: December 19, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Patent number: 11840703
    Abstract: The disclosure provides methods and constructs for the stable production and isolation of biologically functional recombinant V3, a splice variant of the extracellular matrix proteoglycan versican, as well as the protein product and reagents for detecting the same. In one embodiment, the disclosure provides expression systems for expressing rV3. In one embodiment, the disclosure provides an expression system that properly N-glycosylates mammalian proteins, such as V3. In another embodiment, rV3 has been isolated and purified. In another embodiment, the disclosure provides a unique expression construct containing a ubiquitous chromatin opening element upstream of a strong promoter which drives expression of recombinant V3. In yet a further embodiment, the disclosure provides an isolated and purified recombinant V3 protein in amounts suitable for testing and use, and in pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: December 12, 2023
    Inventors: Thomas N. Wight, Mervyn J. Merrilees, Gernot Kaber, Ingrid A. Harten, Michael G. Kinsella